In May 2013, Trevena and Actavis plc entered into an option agreement and a license agreement for the development of TRV027 for acute heart failure.
In 2012 Trevena entered into a collaboration with Merck to characterize signaling pathways downstream of a specific GPCR using Trevena's proprietary assays and know-how.
In December 2011, The Michael J. Fox Foundation awarded Trevena a grant supporting pathway validation experiments to demonstrate the potential of novel biased ligands to the delta opioid receptor as potential treatments for Parkinson's disease.
In August 2011, Trevena secured an award through the NIH Blueprint Neurotherapeutics Network to develop a novel biased ligand to the delta opioid receptor for major depressive disorder.
In October 2010, Trevena received a grant for $0.75 million as part of the federal Qualifying Therapeutic Discovery Project program to offset costs for its drug discovery programs.
Trevena secured business financing administered by the Pennsylvania Department of Community and Economic Development (DCED) in November 2009, designed to stimulate the growth and assist in the retention of emerging and promising Pennsylvania businesses.
Copyright © Trevena, Inc.